Overview

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenstrm Macroglobulinemia

Status:
RECRUITING

Trial end date:
2032-10-01

Target enrollment:

Participant gender:

Summary

This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenstrm macroglobulinemia (WM). The name of the study drug involved in this study is: -Pacritinib (a type of kinase inhibitor)

Phase:

PHASE2

Details

Lead Sponsor:

Shayna Sarosiek, MD

Collaborator:

Sobi, Inc.

Treatments:

11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene